AAPL 193.32 +0.46 (+0.24%)MSFT 133.04 +0.1 (+0.08%)FB 181.4 +1.03 (+0.57%)ZNGA 6.2 +0.08 (+1.23%)NVDA 144.91 +0.48 (+0.33%)WBA 52.67 +0.01 (+0.02%)GOOG 1088.38 +1.34 (+0.12%)PIH 5.73 0 (0.00%)
AAPL 193.32 +0.46 (+0.24%)MSFT 133.04 +0.1 (+0.08%)FB 181.4 +1.03 (+0.57%)ZNGA 6.2 +0.08 (+1.23%)NVDA 144.91 +0.48 (+0.33%)WBA 52.67 +0.01 (+0.02%)GOOG 1088.38 +1.34 (+0.12%)PIH 5.73 0 (0.00%)

Balance Sheet ACOR Quote Acorda Ther

All | Income Statement | Balance Sheet | Cash Flow | Retained Earnings | PPE Schedule | Intangible and Goodwill Schedule
Year 20142015201620172018
CashAndCashEqui 182 153 159 307 294
ShortTermInvest 125 200 0 0 152
Cash 308 353 159 0 0
AccountReceivab 32 31 52 0 0
Inventories 27 36 43 0 0
DeferredIncomeT 0 2 4 0 0
OtherCurrentAss 9 14 6 2 11
TotalCurrentAss 409 451 273 442 528
PPE 60 66 74 87 117
AccumulatedDepr -14 -26 -40 -50 -57
NetPPE 46 40 34 37 61
EquityAndOtherI 0 0 0 0 0
Goodwill 183 184 281 287 282
IntangibleAsset 433 431 742 431 429
OtherLTAssets 10 8 8 2 0
TotalNonCurrent 672 665 1,070 756 772
TotalAssets 1,081 1,116 1,342 1,198 1,300
ShortTermDebt 1 1 1 0 0
AccountsPayable 20 17 30 0 0
TaxesPayable 0 0 0 0 0
AccruedLiabilit 41 49 84 0 0
DeferredRevenue 38 9 9 9 0
OtherCurrentLia 14 14 24 20 36
TotalCurrentLia 114 91 148 144 140
Debt 290 297 299 0 0
DeferredTaxesLi 24 12 93 22 7
DeferredRevenue 51 42 32 23 0
OtherLTLiabilit 62 72 106 179 221
TotalNonCurrent 426 423 530 534 547
TotalLiabilitie 540 513 678 678 688
CommonStock 0 0 0 0 0
AdditionalPaidI 761 813 921 969 1,005
RetainedEarning -220 -209 -244 -455 -394
AccumulatedOthe 0 0 -13 7 3
TotalStockholde 540 603 664 520 612
TotalLiabilitie 1,081 1,116 1,342 1,198 1,300
Acorda Therapeutics Inc. income statement is the only one that provides an overview of company sales and net income
The reasoning behind the adjustment, however, is that free cash flow is meant to measure money being spent right now, not transactions that happened in the past. This makes Acorda Therapeutics Inc. FCF a useful instrument for identifying growing companies with high up-front costs, which may eat into earnings now but have the potential to pay off later.